Tesofensine
Triple monoamine reuptake inhibitor investigated for obesity and neurologic disease. Human studies reported weight-loss signals alongside stimulant-like and cardiovascular effects; it is not an approved routine weight-loss drug in the United States.
Pharmacokinetic model
A route-level PK model for tesofensine is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Investigational Medicine
- Suggested cadence
- once daily
Research behind this entry
-
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease
Post hoc analysis of neurologic-disease trials identified weight loss during tesofensine treatment. It was not a purpose-built obesity efficacy trial and cannot establish general long-term benefit-risk.
-
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users
Controlled human abuse-liability study characterized subjective and physiologic effects in stimulant users. It informs safety and misuse risk, not weight-loss effectiveness.
2 published studies referenced in the app, each with a plain-language summary.